.
MergerLinks Header Logo

Announced

Completed

Stanley Capital completed the acquisition of Noden Pharmaceutical Business from PDL BioPharma for $53m.

Financials

Edit Data
Transaction Value£41m
Consideration TypeCash, Contingent Deferred Consideration
Capital Owned-
Capital Bid For100%
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Tags

Edit

prescription medicines

Friendly

Majority

Pharmaceuticals

Cross Border

Acquisition

Ireland

Private

Single Bidder

United States

Private Equity

Completed

Synopsis

Edit

Stanley Capital, a private equity partnership, completed the acquisition of Noden Pharma DAC and Noden Pharma USA, a global speciality pharmaceutical company that is focused on acquiring prescription medicines across a range of therapeutic areas, from PDL BioPharma, which acquires, manages and commercializes commercial-stage pharmaceutical assets and late clinical-stage pharmaceutical products, for $53m. "After running an extensive process, we are excited about closing this transaction with Stanley Capital. It represents the completion of a key divestiture for PDL and an exciting opportunity for the Noden team," Dominique Monnet, PDL's President and CEO.

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US